PE20240807A1 - Composiciones, metodos y sistemas para la administracion de farmacos en aerosol - Google Patents
Composiciones, metodos y sistemas para la administracion de farmacos en aerosolInfo
- Publication number
- PE20240807A1 PE20240807A1 PE2024000057A PE2024000057A PE20240807A1 PE 20240807 A1 PE20240807 A1 PE 20240807A1 PE 2024000057 A PE2024000057 A PE 2024000057A PE 2024000057 A PE2024000057 A PE 2024000057A PE 20240807 A1 PE20240807 A1 PE 20240807A1
- Authority
- PE
- Peru
- Prior art keywords
- salts
- refers
- methods
- pharmaceutical composition
- aerosol
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000443 aerosol Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- CDOOAUSHHFGWSA-OWOJBTEDSA-N (e)-1,3,3,3-tetrafluoroprop-1-ene Chemical compound F\C=C\C(F)(F)F CDOOAUSHHFGWSA-OWOJBTEDSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940125390 short-acting beta agonist Drugs 0.000 abstract 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 1
- 239000001110 calcium chloride Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960002848 formoterol Drugs 0.000 abstract 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940071648 metered dose inhaler Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220362P | 2021-07-09 | 2021-07-09 | |
| US202163282356P | 2021-11-23 | 2021-11-23 | |
| PCT/US2022/036543 WO2023283439A1 (en) | 2021-07-09 | 2022-07-08 | Compositions, methods and systems for aerosol drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240807A1 true PE20240807A1 (es) | 2024-04-18 |
Family
ID=82748203
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000057A PE20240807A1 (es) | 2021-07-09 | 2022-07-08 | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol |
| PE2024000056A PE20241067A1 (es) | 2021-07-09 | 2022-07-08 | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol |
| PE2024000058A PE20240808A1 (es) | 2021-07-09 | 2022-07-08 | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000056A PE20241067A1 (es) | 2021-07-09 | 2022-07-08 | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol |
| PE2024000058A PE20240808A1 (es) | 2021-07-09 | 2022-07-08 | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20240252440A1 (https=) |
| EP (6) | EP4393478A3 (https=) |
| JP (3) | JP2024525555A (https=) |
| KR (3) | KR20240042436A (https=) |
| AU (3) | AU2022305962A1 (https=) |
| CA (3) | CA3226557A1 (https=) |
| CL (3) | CL2024000041A1 (https=) |
| CO (3) | CO2024000631A2 (https=) |
| CR (3) | CR20240064A (https=) |
| DK (3) | DK4197528T3 (https=) |
| DO (3) | DOP2024000004A (https=) |
| EC (1) | ECSP24011022A (https=) |
| ES (3) | ES2983201T3 (https=) |
| FI (3) | FI4175620T3 (https=) |
| HR (3) | HRP20240716T1 (https=) |
| HU (3) | HUE067283T2 (https=) |
| IL (3) | IL309888A (https=) |
| LT (3) | LT4175619T (https=) |
| MA (3) | MA60224B1 (https=) |
| MX (3) | MX2024000465A (https=) |
| PE (3) | PE20240807A1 (https=) |
| PL (3) | PL4197528T3 (https=) |
| PT (3) | PT4175619T (https=) |
| RS (3) | RS65598B1 (https=) |
| SI (3) | SI4175620T1 (https=) |
| SM (3) | SMT202400370T1 (https=) |
| TW (3) | TW202317079A (https=) |
| WO (3) | WO2023283439A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250345292A1 (en) * | 2022-04-28 | 2025-11-13 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
| CN116270464B (zh) * | 2023-03-01 | 2025-09-30 | 深圳市贝美药业有限公司 | 一种克立硼罗气雾剂及其制备方法 |
| FR3150798B1 (fr) | 2023-07-07 | 2025-11-21 | Aptar France Sas | Dispositif de distribution de produit fluide |
| WO2025179277A1 (en) | 2024-02-23 | 2025-08-28 | Zelicovich Marcelo Lazaro | Aerosol delivery system with enhanced air suspension |
| TW202600144A (zh) * | 2024-02-23 | 2026-01-01 | 瑞典商阿斯特捷利康公司 | Copd之三重組合療法 |
| WO2026006658A1 (en) * | 2024-06-27 | 2026-01-02 | Lupin Inc. | Stable pharmaceutical compositions for pressurized metered dose inhalers |
| US20260007598A1 (en) * | 2024-07-05 | 2026-01-08 | Honeywell International Inc. | Compositions, devices and methods for respritory delivery of active pharmaceutical ingredients |
| GB202410910D0 (en) * | 2024-07-25 | 2024-09-11 | Bespak Europe Ltd | Method of filling a pressurised dispensing container and filled pressurised dispensing container |
| US12496272B1 (en) | 2024-07-31 | 2025-12-16 | Amphastar Pharmaceuticals, Inc. | Stable epinephrine suspension formulation for inhalation with HFO propellant |
| US12383516B1 (en) | 2025-01-06 | 2025-08-12 | Amphastar Pharmaceuticals, Inc. | Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US37872A (en) | 1863-03-10 | Improved mast-hoop | ||
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| SE378109B (https=) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US4187301A (en) | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
| BE887518A (fr) | 1980-02-15 | 1981-08-13 | Glaxo Group Ltd | Cartothioates d'androstanes |
| CY1359A (en) | 1981-02-02 | 1987-08-07 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| US5707634A (en) | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| SE9404080L (sv) | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| ATE287703T1 (de) | 1995-04-14 | 2005-02-15 | Nektar Therapeutics | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| US5886200A (en) | 1996-07-01 | 1999-03-23 | Schering Corporation | Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| NZ500555A (en) | 1999-08-02 | 2000-11-24 | Hovione Int Ltd | Process for the preparation of mometasone furoate |
| NZ518401A (en) | 1999-10-29 | 2004-01-30 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
| PT1280520E (pt) | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| SI3170880T1 (sl) | 2002-10-25 | 2020-07-31 | Honeywell International Inc. | Uporaba sestavkov, ki kot hladilni sestavek vsebujejo HFO-1234ZE ali HFO-1234YF |
| US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| ES2335498T3 (es) | 2003-03-10 | 2010-03-29 | Nycomed Gmbh | Nuevo proceso para la preparacion de reflumilast. |
| KR20060015316A (ko) | 2003-05-28 | 2006-02-16 | 넥타르 테라퓨틱스 | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법 |
| US9308199B2 (en) | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
| AU2006272438B2 (en) | 2005-07-15 | 2011-08-04 | Map Pharmaceuticals, Inc. | Method of particle formation |
| CN100560598C (zh) | 2005-07-26 | 2009-11-18 | 上海奥锐特国际贸易有限公司 | 氟替卡松丙酸酯的合成方法 |
| CA2669924A1 (en) * | 2006-11-20 | 2008-05-29 | Cipla Limited | An aerosol device |
| US8815258B2 (en) * | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| PL3111927T3 (pl) | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy |
| SG181870A1 (en) * | 2009-12-23 | 2012-07-30 | Chiesi Farma Spa | Aerosol formulation for copd |
| RU2013155903A (ru) * | 2011-05-17 | 2015-06-27 | Перл Терапьютикс, Инк. | Композиции, способы и устройства для респираторной доставки двух или более активных средств |
| CN104080770A (zh) | 2011-11-09 | 2014-10-01 | 迈兰实验室有限公司 | 用于制备罗氟司特的改进方法 |
| CN107596518B (zh) * | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| WO2014060464A1 (en) | 2012-10-17 | 2014-04-24 | Interquim, S.A. | Process for preparing roflumilast |
| HUE052275T2 (hu) * | 2013-01-28 | 2021-04-28 | Incozen Therapeutics Pvt Ltd | Eljárások autoimmun, légzõszervi és gyulladásos rendellenességek kezelésére roflumilaszt N-oxid inhalálásával |
| US20150150787A1 (en) * | 2013-05-22 | 2015-06-04 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of three or more active agents |
| ES2970740T3 (es) | 2017-10-09 | 2024-05-30 | Pearl Therapeutics Inc | Unidad de administración de aerosol |
-
2022
- 2022-07-08 CA CA3226557A patent/CA3226557A1/en active Pending
- 2022-07-08 KR KR1020247004328A patent/KR20240042436A/ko active Pending
- 2022-07-08 EP EP24161253.0A patent/EP4393478A3/en active Pending
- 2022-07-08 MA MA60224A patent/MA60224B1/fr unknown
- 2022-07-08 PL PL23155432.0T patent/PL4197528T3/pl unknown
- 2022-07-08 SM SM20240370T patent/SMT202400370T1/it unknown
- 2022-07-08 MX MX2024000465A patent/MX2024000465A/es unknown
- 2022-07-08 KR KR1020247004330A patent/KR20240042438A/ko active Pending
- 2022-07-08 TW TW111125752A patent/TW202317079A/zh unknown
- 2022-07-08 US US18/577,168 patent/US20240252440A1/en active Pending
- 2022-07-08 DK DK23155432.0T patent/DK4197528T3/da active
- 2022-07-08 HU HUE22751897A patent/HUE067283T2/hu unknown
- 2022-07-08 US US17/861,072 patent/US20230026203A1/en not_active Abandoned
- 2022-07-08 CR CR20240064A patent/CR20240064A/es unknown
- 2022-07-08 SI SI202230039T patent/SI4175620T1/sl unknown
- 2022-07-08 MX MX2024000467A patent/MX2024000467A/es unknown
- 2022-07-08 LT LTEPPCT/US2022/036543T patent/LT4175619T/lt unknown
- 2022-07-08 WO PCT/US2022/036543 patent/WO2023283439A1/en not_active Ceased
- 2022-07-08 FI FIEP22751897.4T patent/FI4175620T3/fi active
- 2022-07-08 TW TW111125764A patent/TW202317080A/zh unknown
- 2022-07-08 US US18/577,176 patent/US20240252432A1/en active Pending
- 2022-07-08 WO PCT/US2022/036542 patent/WO2023283438A1/en not_active Ceased
- 2022-07-08 HU HUE23155432A patent/HUE067547T2/hu unknown
- 2022-07-08 TW TW111125791A patent/TW202317081A/zh unknown
- 2022-07-08 HU HUE22748656A patent/HUE067281T2/hu unknown
- 2022-07-08 WO PCT/US2022/036548 patent/WO2023283441A1/en not_active Ceased
- 2022-07-08 SI SI202230041T patent/SI4175619T1/sl unknown
- 2022-07-08 SM SM20240368T patent/SMT202400368T1/it unknown
- 2022-07-08 FI FIEP22748656.0T patent/FI4175619T3/fi active
- 2022-07-08 AU AU2022305962A patent/AU2022305962A1/en active Pending
- 2022-07-08 HR HRP20240716TT patent/HRP20240716T1/hr unknown
- 2022-07-08 LT LTEP23155432.0T patent/LT4197528T/lt unknown
- 2022-07-08 ES ES22751897T patent/ES2983201T3/es active Active
- 2022-07-08 EP EP24161189.6A patent/EP4393477A3/en active Pending
- 2022-07-08 RS RS20240630A patent/RS65598B1/sr unknown
- 2022-07-08 PL PL22751897.4T patent/PL4175620T3/pl unknown
- 2022-07-08 RS RS20240629A patent/RS65597B1/sr unknown
- 2022-07-08 HR HRP20240753TT patent/HRP20240753T1/hr unknown
- 2022-07-08 CR CR20240063A patent/CR20240063A/es unknown
- 2022-07-08 JP JP2024500203A patent/JP2024525555A/ja active Pending
- 2022-07-08 DK DK22748656.0T patent/DK4175619T3/da active
- 2022-07-08 SM SM20240312T patent/SMT202400312T1/it unknown
- 2022-07-08 PE PE2024000057A patent/PE20240807A1/es unknown
- 2022-07-08 EP EP22748658.6A patent/EP4366695A1/en active Pending
- 2022-07-08 ES ES22748656T patent/ES2981514T3/es active Active
- 2022-07-08 MA MA60223A patent/MA60223B1/fr unknown
- 2022-07-08 JP JP2024500250A patent/JP2024525567A/ja active Pending
- 2022-07-08 JP JP2024500201A patent/JP2024527348A/ja active Pending
- 2022-07-08 CA CA3226153A patent/CA3226153A1/en active Pending
- 2022-07-08 PT PT227486560T patent/PT4175619T/pt unknown
- 2022-07-08 MX MX2024000468A patent/MX2024000468A/es unknown
- 2022-07-08 HR HRP20240725TT patent/HRP20240725T1/hr unknown
- 2022-07-08 PE PE2024000056A patent/PE20241067A1/es unknown
- 2022-07-08 CR CR20240066A patent/CR20240066A/es unknown
- 2022-07-08 PE PE2024000058A patent/PE20240808A1/es unknown
- 2022-07-08 IL IL309888A patent/IL309888A/en unknown
- 2022-07-08 ES ES23155432T patent/ES2981709T3/es active Active
- 2022-07-08 IL IL309907A patent/IL309907A/en unknown
- 2022-07-08 AU AU2022306682A patent/AU2022306682A1/en active Pending
- 2022-07-08 IL IL309908A patent/IL309908A/en unknown
- 2022-07-08 PT PT227518974T patent/PT4175620T/pt unknown
- 2022-07-08 EP EP22748656.0A patent/EP4175619B1/en active Active
- 2022-07-08 FI FIEP23155432.0T patent/FI4197528T3/fi active
- 2022-07-08 AU AU2022308837A patent/AU2022308837A1/en active Pending
- 2022-07-08 PL PL22748656.0T patent/PL4175619T3/pl unknown
- 2022-07-08 DK DK22751897.4T patent/DK4175620T3/da active
- 2022-07-08 RS RS20240576A patent/RS65537B1/sr unknown
- 2022-07-08 KR KR1020247004329A patent/KR20240042437A/ko active Pending
- 2022-07-08 CA CA3226155A patent/CA3226155A1/en active Pending
- 2022-07-08 PT PT231554320T patent/PT4197528T/pt unknown
- 2022-07-08 EP EP22751897.4A patent/EP4175620B1/en active Active
- 2022-07-08 US US18/577,165 patent/US20240358662A1/en active Pending
- 2022-07-08 MA MA61888A patent/MA61888B1/fr unknown
- 2022-07-08 LT LTEPPCT/US2022/036542T patent/LT4175620T/lt unknown
- 2022-07-08 SI SI202230038T patent/SI4197528T1/sl unknown
- 2022-07-08 EP EP23155432.0A patent/EP4197528B1/en active Active
-
2024
- 2024-01-03 DO DO2024000004A patent/DOP2024000004A/es unknown
- 2024-01-04 DO DO2024000005A patent/DOP2024000005A/es unknown
- 2024-01-05 CL CL2024000041A patent/CL2024000041A1/es unknown
- 2024-01-05 DO DO2024000006A patent/DOP2024000006A/es unknown
- 2024-01-05 CL CL2024000039A patent/CL2024000039A1/es unknown
- 2024-01-05 CL CL2024000037A patent/CL2024000037A1/es unknown
- 2024-01-25 CO CONC2024/0000631A patent/CO2024000631A2/es unknown
- 2024-01-26 CO CONC2024/0000742A patent/CO2024000742A2/es unknown
- 2024-01-26 CO CONC2024/0000748A patent/CO2024000748A2/es unknown
- 2024-02-09 EC ECSENADI202411022A patent/ECSP24011022A/es unknown
- 2024-02-28 US US18/590,826 patent/US20240325298A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240807A1 (es) | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol | |
| PE20011323A1 (es) | Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis | |
| AR130239A2 (es) | Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de una lata de aerosol asociada | |
| CL2022002235A1 (es) | Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada | |
| MX340924B (es) | Composiciones farmaceuticas. | |
| PE20160853A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) | |
| MX2021009476A (es) | Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano. | |
| MX2024002497A (es) | Inhaladores de dosis medida y composiciones en solucion. | |
| CO2022012207A2 (es) | Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada | |
| AR101593A2 (es) | Formulación superfina de formoterol | |
| ME02342B (me) | Farmaceutske formulacije rastvora za izmjerene doze inhalatora pod pritiskom | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| CL2023000998A1 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
| JP2019528316A5 (https=) | ||
| HRP20231729T1 (hr) | Kombinirana terapija za kopb | |
| ES2247959T1 (es) | Formulacion medica en aerosol estabilizada en agua. | |
| PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
| AR099963A2 (es) | Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenar | |
| JP2004529108A5 (https=) | ||
| CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
| ES2259915B1 (es) | Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion. | |
| AR085443A1 (es) | Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero | |
| BR102012027127A2 (pt) | Composição contida em um inalador farmacêutico pressurizado com medidores de dosagem | |
| AR103475A1 (es) | Un medicamento inhalable | |
| CO2024017482A2 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas |